Loading
A phase 2 trial of Poziotinib in Breast cancer and Colorectal cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies is a phase 2 interventional study registered as NCT04172597 by Spectrum Pharmaceuticals, Inc, with 1 participants recorded, started 2019-12-23 and due to reach its primary completion in 2022-03-29. Interventions recorded: Poziotinib Hydrochloride, Loperamide. Conditions recorded: Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme.
Linked to the drug Poziotinib because the registry names it among its interventions and Breast cancer and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares Poziotinib, Spectrum Pharmaceuticals, Breast cancer (all types) and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Spectrum Pharmaceuticals and the tag pipeline.
Shares Breast cancer (all types), Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.